Value in Health Regional Issues

Slides:



Advertisements
Similar presentations
Volume 14, Issue 8, Pages (December 2011)
Advertisements

Value in Health Regional Issues
Volume 15, Issue 8, Pages (December 2012)
Volume 15, Issue 1, Pages S20-S28 (January 2012)
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Volume 15, Issue 2, Pages (March 2012)
Volume 14, Issue 8, Pages (December 2011)
Volume 17, Issue 2, Pages (March 2014)
Value in Health Regional Issues
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine.
Value in Health Regional Issues
Value in Health Regional Issues
Value in Health Regional Issues
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Value in Health Regional Issues
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
The Cost-Effectiveness Analysis of a Quadrivalent Human Papillomavirus Vaccine (6/11/16/18) for Females in Japan  Kaoru Yamabe, MSc, Puneet K. Singhal,
Cost-Effectiveness of Introducing Point-of-Care Test for Detection of Level of Glycogen Phosphorylase in Early Diagnostic Algorithm of Acute Coronary.
Cost-Effectiveness Analysis of Hepatitis B Immunization in Vietnam: Application of Cost- Effectiveness Affordability Curves in Health Care Decision Making 
Value in Health Regional Issues
Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico  Kely Rely, Rosa María.
Value in Health Regional Issues
The Process of Privatization of Health Care Provision in Poland
Value in Health Regional Issues
Value in Health Regional Issues
Cost-Effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam  Lan Hoang Nguyen, Wongsa Laohasiriwong, John Frederick Stewart, Pamela.
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Value in Health Regional Issues
The role of vaccination in preventing pneumococcal disease in adults
Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease—A Meta-Analysis.
Value in Health Regional Issues
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore  Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,
What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.
Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia in Guatemala  Benjamin Cruz Rodriguez, MD, Sergio Leal, MD, Gonzalo Calvimontes,
Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire  Bhavik Shah,
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
Burden of Disease and Economic Impact of Dengue and Severe Dengue in Colombia, 2011  Carlos Castañeda-Orjuela, MD, MSc, Hernando Díaz, PhD, Nelson Alvis-Guzman,
Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia 
Value in Health Regional Issues
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Value in Health Regional Issues
Omneya Mohamed, PhD, David H. Kreling, PhD 
Value in Health Regional Issues
Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy?  Fei-Li.
Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary  András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand  Panrasri Khonputsa,
Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes  Maxwell O. Adibe,
Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?  Chun-Ru Chien, MD, PhD, Ya-Chen Tina.
Cost-effectiveness Analysis of Viscosupplementation versus Conventional Supportive Therapy for Knee Osteoarthritis in Colombia  Juan-Carlos Castro, MD,
Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan  Yoshie Onishi, MS,
Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers  Valentina.
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Value in Health Regional Issues
Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L.
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not.
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Social Cost of Substance Abuse in Russia
Anut Sakulsupsiri, MSc, Phantipa Sakthong, PhD, Win Winit-Watjana, PhD 
Economic Evaluation of Four Drug Administration Systems in Intensive Care Units in Colombia  Diego Rosselli, MD, MSc, Juan David Rueda, MD, María Daniela.
Clinical Burden of Invasive Pneumococcal Disease in Selected Developing Countries  Namaitijiang Maimaiti, PhD, Zafar Ahmed, PhD, Zaleha Md Isa, PhD, Hasanain.
Victoria I. Ignatyeva, MPH, Johan L
A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina  Joaquín.
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.
Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov.
One-way sensitivity analysis.
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
Presentation transcript:

Value in Health Regional Issues Cost-Effectiveness Analysis of Pneumococcal Vaccination with the Pneumococcal Polysaccharide NTHi Protein D Conjugate Vaccine in the Philippines  Xu-Hao Zhang, PhD, Maria Carmen Nievera, MD, Josefina Carlos, MD, Marilla Lucero, MD, PhD, Gyneth Bibera, MD, Maria Isabel Atienza, MD, Oleksandr Topachevskyi, PGDip, Cecilia Gretchen Navarro-Locsin, MD  Value in Health Regional Issues  Volume 3, Pages 156-166 (May 2014) DOI: 10.1016/j.vhri.2014.04.004 Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Markov cohort model design. The cohort model is Markov-based with three exclusive health states: no disease, sequelae, and death. The transition from “no disease” to “sequelae” or “death” is calculated on the basis of this decision tree. In the model, only meningitis can lead to long-term sequelae; meningitis and bacteremia include NTHi meningitis and NTHi bacteremia, respectively; and nonconsulting AOM are accounted for in the quality-of-life impact calculation. AOM, acute otitis media; GP, general practitioner; NTHi, nontypeable Haemophilus influenzae; PCP, primary care physician; PCV13, pneumococcal 13-valent conjugate vaccine; PHiD-CV, pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D conjugate vaccine. Value in Health Regional Issues 2014 3, 156-166DOI: (10.1016/j.vhri.2014.04.004) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Tornado diagram for the top 10 most influential parameters of the cost-effectiveness analysis of PHiD-CV 2 + 1 vaccination program versus no vaccination (one-way sensitivity analysis) in the Philippines. AOM, acute otitis media; CI, confidence interval; CAP, community-acquired pneumonia; GP, general practitioner; NTHi, nontypeable Haemophilus influenzae; PHiD-CV, pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D conjugate vaccine. Value in Health Regional Issues 2014 3, 156-166DOI: (10.1016/j.vhri.2014.04.004) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 3 Univariate sensitivity analysis comparing PHiD-CV with PCV13 in the Philippines. The effect of the nine most influential variables on cost-effectiveness results of the PHiD-CV 2 + 1 vaccination program versus the PCV13 2 + 1 strategy. AOM, acute otitis media; CI, confidence interval; GP, general practitioner; LL, lower limit; NTHi, nontypeable Haemophilus influenzae; PCV13, pneumococcal 13-valent conjugate vaccine; PHiD-CV, pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D conjugate vaccine; QALY, quality-adjusted life-year; UL, upper limit. Value in Health Regional Issues 2014 3, 156-166DOI: (10.1016/j.vhri.2014.04.004) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 4 Cost-effectiveness plane of probabilistic sensitivity analysis comparing PHiD-CV 2 + 1 with the no-vaccination strategy in the Philippines. PHiD-CV, pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D conjugate vaccine; QALY, quality-adjusted life-year. Value in Health Regional Issues 2014 3, 156-166DOI: (10.1016/j.vhri.2014.04.004) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 5 Cost-effectiveness plane of probabilistic sensitivity analysis comparing PHiD-CV 2 + 1 with no PCV13 2 + 1 in the Philippines. PCV13, pneumococcal 13-valent conjugate vaccine; PHiD-CV, pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D conjugate vaccine’ QALY, quality-adjusted life-year. Value in Health Regional Issues 2014 3, 156-166DOI: (10.1016/j.vhri.2014.04.004) Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions